哈药股份(600664.SH)：蛋白琥珀酸铁获得化学原料药上市申请批准通知书

Core Viewpoint - The approval of the chemical raw material drug application for Ferric Succinylate by the National Medical Products Administration marks a significant advancement for the company in the raw material drug sector, enhancing its strategic development and product structure [1] Group 1: Company Developments - The company’s subsidiary, Harbin Pharmaceutical Group Sanjing Ming Water Pharmaceutical Co., Ltd., received the approval notice for Ferric Succinylate [1] - This approval is a crucial step in the company's strategy to achieve self-control over its raw material drugs [1] - The approval will further solidify the company's integrated development strategy of raw materials and formulations, benefiting the diversification of its product structure [1]